ORIC Pharmaceuticals, Inc. (ORIC) Discusses Enozertinib Phase Ib Data and Commercial Opportunity in EGFR Atypical Non-Small Cell Lung Cancer TranscriptSeeking Alpha · 1 day ago
Oric Pharmaceuticals' Enozertinib Shows 88% Response Rate in EGFR Lung Cancer StudyMarketBeat · 1 day ago
ORIC® Pharmaceuticals Presents Potential Best-in-Class Data for Enozertinib in 1L NSCLC Patients with EGFR Atypical Mutations at ESMO Congress 2026 and Plans to Advance Enozertinib into a Global Phase 3 TrialGlobeNewsWire · 1 day ago
ORIC® Pharmaceuticals Presents Preclinical and Translational Data to Support the Potential of Rinzimetostat to Enhance Sensitivity to Androgen Receptor Inhibition in Prostate Cancer at ESMO Congress 2026GlobeNewsWire · 1 day ago
ORIC® Pharmaceuticals to Host Conference Call & Webcast to Review Enozertinib Data Being Presented at ESMO Congress 2026GlobeNewsWire · 5 days ago
ORIC® Pharmaceuticals Announces Agreement with Cancer Research UK to Advance a Potential First-in-Class CIP2A-Targeted Therapy Into Clinical DevelopmentGlobeNewsWire · Oct 5, 2026ORIC Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative treatments for cancer patients across the United States. The company's pipeline includes several key clinical-stage drug candidates. ORIC-533 is an oral small molecule designed to inhibit CD73, addressing resistance to both chemotherapy and immunotherapy.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 3, 2026 | -$0.36 | -$0.38 | Miss |
| May 4, 2026 | -$0.32 | -$0.34 | Miss |
| Feb 23, 2026 | -$0.34 | -$0.30 | Beat |
| Nov 13, 2025 | -$0.41 | -$0.33 | Beat |
| Aug 12, 2025 | -$0.46 | -$0.47 | Miss |
| May 5, 2025 | -$0.51 | -$0.42 | Beat |